These guidelines were first published in 1999. This 10th edition (2024) has been reviewed by:
Dr Anne Robertson, Consultant Sexual Health Physician and Gynecologist.
Dr Heather Young, Sexual Health Physician.
Dr Dean Ruske - MBChB FRACS, ORL Head and Neck Surgery Consultant.
Dr Silvana Campanella, Paediatrician, Te Puaruruhau.
Dr Ron Jones.
Katie McCullough, Nurse Practitioner, Clinical Lead, STIEF.
Edited by Nicola Ryan.
1st Edition 1999
2nd Edition 2001
3rd Edition 2002
4th Edition 2004
5th Edition 2007
6th Edition 2010
7th Edition 2013
8th Edition 2015
9th Edition 2017
10th Edition 2024
Promoting optimal sexual health outcomes for all peoples in Aotearoa New Zealand.
E whakatairanga ana i ngā putanga hauora onioni papai mō ngā iwi katoa o Aotearoa.
New Zealand HPV Project: www.hpv.org.nz
New Zealand Herpes Foundation: www.herpes.org.nz
Just the Facts: www.justthefacts.co.nz
HPV and Herpes Helpline - 0508 11 12 13 from a landline or 09 433 6526 from a mobile
Guidelines for the Management of Genital Herpes in Aotearoa New Zealand: www.guidelines.stief.org.nz
Email: info@stief.org.nz
New Zealand Sexual Health Society (NZSHS) resources: Comprehensive STI Management Guidelines and Patient Information handouts are available on www.nzshs.org/guidelines
National Cervical Screening Programme (NCSP) resources on HPV testing/screening: https://www.tewhatuora.govt.nz/health-services-and-programmes/ncsp-hpv-screening/understand-hpv-primary-screening/
World Health Organisation resources on HPV, related cancer and vaccines: https://www.who.int/news-room/fact-sheets/detail/human-papilloma-virus-and-cancer
Centre for disease control resources on HPV treatment guidelines:
https://www.cdc.gov/std/treatment-guidelines/hpv.htm
Sexually Transmitted Infections Education Foundation. Guideline for the Management of Genital, Anal and Throat HPV Infection in Aotearoa New Zealand: 10th Edition. 2024. Available at: https://guidelines.stief.org.nz/hpv
The Aotearoa New Zealand HPV guidelines were first developed in 1999. The 2024 (10th) edition has been updated to reference changes to the National Cervical Screening Programme and advances in the management of anal cancer pre-cursors. In addition, the different guideline chapters are now presented as individual documents to improve accessibility.
The authors and review team of these guideline documents includes representation from patients, and medical and nursing disciplines involved in the management of people with anogenital HPV and/or genital warts. Contemporary international literature has been evaluated to develop best practice regarding the diagnosis, treatment and evaluation of patients with HPV infection/genital warts and their sexual partners in Aotearoa New Zealand. The recommendations are based on strong evidence in the literature or reasonable supposition and expert opinion.
The information contained here is accurate at the time of publication.
The recommendations made in the guidelines have been rated using the following evidence-based categories:
Grade A: Very strong evidence
One or more properly randomised controlled clinical trials.
Grade B: Fairly strong evidence
One or more well-designed observational studies (i.e. non-randomised clinical trial, cohort, case control or time series study, or uncontrolled experimental trials).
Grade C: Weak evidence or firmly held opinion
Opinions of respected authorities that were based on clinical experience, descriptive studies, and/or reports of expert committees.
AIN anal intraepithelial neoplasia
AIS adenocarcinoma in situ
ASC-H atypical squamous cells – a High-grade lesion cannot be excluded
ASC-US atypical squamous cells of undetermined significance
CIN 1, 2 or 3 cervical intraepithelial neoplasia (1 = low grade, 2 or 3 = high grade)
HPV human papillomavirus
hrHPV high-risk human papillomavirus
HSIL high-grade squamous intraepithelial lesion
LBC liquid-based cytology
lrHPV low-risk human papillomavirus
LSIL low-grade squamous intraepithelial lesion
MSM men who have sex with men
NCSP National Cervical Screening Programme
PCR polymerase chain reaction amplification
PIN penile intraepithelial neoplasia
RRP recurrent respiratory papillomatosis
SCC squamous cell carcinoma
SIL squamous intraepithelial lesion
STI sexually transmitted infection
TCA trichlorocetic acid
VIN vulval intraepithelial neoplasia
VLP virus-like particle
The Ministry of Health supports the use of these clinical guidelines, developed by clinical experts and professional associations to guide clinical care.
Produced by the Professional Advisory Board (PAG) of the Sexually Transmitted Infections Education Foundation
Sexually Transmitted Infections Education Foundation
Website by Original Image